Aim: Although current guidelines recommend 3-6 months of dual antiplatelet therapy (DAPT) for patients without indications for anticoagulation after transcatheter aortic valve replacement (TAVR), evidence-based evidence was lacking. Our aim was to review the most recent evidence comparing the safety and efficacy of both treatment modalities, single antiplatelet therapy (SAPT) and DAPT, after TAVR. Methods: We systematically searched the literature on Embase, PubMed, Cochrane and Medline until January 5, 2022. Our primary outcome indicators were: all-cause mortality, stroke and total bleeding rates, and secondary outcome indicators were: cardiovascular mortality, myocardial infarction (MI) and the incidence of major and life-threatening bleeding (LTB). A random-effects model was used, and subgroup analyses were performed according to study type and follow-up time. Results: A total of 14 studies (4 RCTs, 10 observational studies) involving 21,546 patients were finally screened. Compared with the DAPT treatment modality, patients in the SAPT group showed a significant difference in short-term cardiovascular mortality after TAVR (RR [95% CI] =0.39 [0.19-0.78], P = 0.008) and a significantly lower risk of bleeding (RR [95% CI] =0.56 [0.48-0.65], P <0.001). There was also a significant difference in the incidence of major bleeding and LTB (RR [95% CI] =0.59[0.47-0.76], P <0.0001), but no statistically significant difference in other aspects. Conclusion: Compared with DAPT treatment modalities, the choice of SAPT for patients without anticoagulation indication after TAVR better reduces the risk of postoperative bleeding and short-term cardiovascular death without increasing the incidence of all-cause mortality, stroke, and MI.